176-33-0

Usage

Uses

1. Used in Scientific Research:
1,4-DIOXA-7-AZA-SPIRO[4.4]NONANE is used as a research compound for [application reason] in the field of synthetic chemistry. Its unique structure and properties make it a valuable subject for study and potential applications in various scientific contexts.
2. Used in Chemical Synthesis:
1,4-DIOXA-7-AZA-SPIRO[4.4]NONANE is used as a synthetic intermediate for [application reason] in the production of other chemical compounds. Its heterocyclic nature allows for the creation of complex molecules with potential applications in various industries.
Note: The specific application reasons for 1,4-DIOXA-7-AZA-SPIRO[4.4]NONANE are not provided in the materials, so they are left as placeholders to be filled in with accurate information when available.

InChI:InChI=1/C7H13NO/c1-2-4-7(3-1)8-5-6-9-7/h8H,1-6H2

Upstream product

• 14891-11-3 N-ethoxycarbonyl-3-pyrrolidinone ethylene ketal 
• 139524-57-5 N-(benzyloxycarbonyl)-7-aza-1,4-dioxospiro<4.4>nonane 

Downstream Products

• 139524-59-7 1-(2,4-Difluoro-phenyl)-7-(1,4-dioxa-7-aza-spiro[4.4]non-7-yl)-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester 
• 139524-61-1 1-(2,4-Difluoro-phenyl)-7-(1,4-dioxa-7-aza-spiro[4.4]non-7-yl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester 
• 41234-71-3 7-(2-formyl-benzoyl)-1,4-dioxa-7-aza-spiro[4.4]nonane 
• 23428-86-6 7-(2-hydroxymethyl-benzoyl)-1,4-dioxa-7-aza-spiro[4.4]nonane 
• 23428-82-2 2-(1,4-dioxa-7-aza-spiro[4.4]nonane-7-carbonyl)-benzoic acid methyl ester 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUND

Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.

OXOBENZINDOLIZINOQUINOLINES AND USES THEREOF

The synthesis of aromathecins, substituted 12H-5,l la-diazadibenzo[b,h]fluoren- 11 -ones is described. Use of these cytotoxic compounds and pharmaceutical compositions containing them for the treatment of cancer is described. Two novel processes for the synthesis of this system and a series of 14-substituted aromathecins as novel cytotoxic, topoisomerase I poisons are described.

Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors

The aromathecin or "rosettacin" class of topoisomerase I (top1) inhibitors is effectively a "composite" of the natural products camptothecin and luotonin A and the synthetic indenoisoquinolines. The aromathecins have aroused considerable interest following the isolation and total synthesis of 22-hydroxyacuminatine, a rare cytotoxic natural product containing the 12H-5,11a-diazadibenzo[b,h]fluoren-11-one system. We have developed two novel syntheses of this system and prepared a series of 14-substituted aromathecins as novel antiproliferative topoisomerase I poisons. These inhibitors are proposed to act via an intercalation and "poisoning" mechanism identical to camptothecin and the indenoisoquinolines. Many of these compounds possess greater antiproliferative activity and anti-top 1 activity than the parent unsubstituted compound (rosettacin) and previously synthesized aromathecins, as well as greater top1 inhibitory activity than 22-hydroxyacuminatine. In addition to potentially aiding solubility and localization to the DNA-enzyme complex, nitrogenous substituents located at the 14-position of the aromathecin system have been proposed to project into the major groove of the top1-DNA complex and hydrogen-bond to major-groove amino acids, thereby stabilizing the ternary complex.

Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation

A series of 2-aminoalkylethers prepared as potential antiarrhythmic agents is described. The present compounds are mixed sodium and potassium ion channel blockers and exhibit antiarrhythmic activity in a rat model of ischemia-induced arrhythmias. Structure-activity studies led to the identification of three compounds 5, 18, and 26, which were selected based on their particular in vivo electrophysiological properties, for studies in two canine atrial fibrillation (AF) models. The three compounds converted AF in both models, but only compound 26 was shown to be orally bioavailable. Resolution of the racemate 26 into its corresponding enantiomers 40 and 41 and subsequent biological testing of these enantiomers led to the selection of (1S,2S)-1-(1-naphthalenethoxy)-2-(3- ketopyrrolidinyl)cyclohexane monohydrochloride (41) as a potential atrial selective antiarrhythmic candidate for further development.

AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF

Aminocyclohexyl ether compounds of formula (I), or a solvate or pharmaceutically acceptable salt thereof: are disclosed. In said formula, A, X and R, -R5 have the meanings given in the description. The compounds of the present invention may be inco

Preparation and in Vitro and in Vivo Evaluation of Quinolones with Selective Activity against Gram-Positive Organisms

A series of quinolones were prepared which contained oximes or substituted oximes as replacements for the amine substituents normally found on the pyrrolidine or piperidine fragments of quinolone antibacterial agents.These substituents led to compounds that had selective activity against Gram-positive organisms.These compounds showed in vivo activity Staphylococcus aureus.Only compound 29 had in vivo activity against Streptococcus pneumoniae.